Search results
Patients with mild-to-moderate disease who are at high risk for progression to severe COVID-19 . Treatment with remdesivir for three days in ambulatory patients reduced hospitalizations and COVID-19-related medically attended visits throughout day 28 (HR: 0.28; 95% CI: 0.1, 0.75, low CoE; and HR: 0.19; 95% CI: 0.07, 0.56, low CoE, respectively).
- Paxlovid
This website uses cookies. We use cookies to ensure that we...
- Antigen Testing
December 20, 2022. Version 2.0.0 has been released and...
- Serology
Serologic tests for severe acute respiratory syndrome...
- Training and Resources
Guideline Panelists; Clinical Practice Guidelines...
- AMR Guidance 2.0
This guidance document provides recommendations to...
- Infection Prevention & Control
IDSA submitted comments to FDA's draft guidance for industry...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- State and Regional Societies
Are you interested in launching a relationship between your...
- Paxlovid
Background and objective: Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.
2 gru 2021 · Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.
16 maj 2020 · Our study is the first randomised, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19. The study was terminated before attaining the prespecified sample size.
21 lut 2023 · We conducted a systematic review and individual patient data meta-analysis to evaluate the benefits and harms of remdesivir compared with placebo or usual care in patients treated in hospital for COVID-19 and whether treatment effects differed between subgroups of patients.
10 gru 2020 · Studies evaluating remdesivir in adults with hospitalized COVID-19 were searched in several engines until August 21, 2020. Primary outcomes included all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAEs). Inverse variance random effects meta-analyses were performed. Results.
22 maj 2020 · Abstract. Background. Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be...
